Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells...

Area of Science:

• Immunology
• Cancer Research
• Pharmacology

Background:

• Myeloid-derived suppressor cells (MDSC) play a critical role in tumor immune evasion.
• Cisplatin (DDP) is a widely used chemotherapy agent with known immunomodulatory potential.
• Understanding DDP's effect on MDSC is crucial for optimizing cancer immunotherapy.

Purpose of the Study:

• To investigate the immunomodulatory effects of cisplatin (DDP) on myeloid-derived suppressor cells (MDSC).
• To evaluate the impact of DDP on MDSC frequency, phenotype, and function in a murine B16 melanoma model.
• To assess the combined antitumor effect of DDP and adoptive cytokine-induced killer (CIK) cell therapy.

Main Methods:

• Establishment of a murine B16 melanoma model in C57BL/6 mice.
• Treatment with varying doses of cisplatin (DDP).
• Flow cytometry to analyze MDSC percentages and phenotype.
• CFSE-labeling assay, interferon-γ detection, and MTT assay to assess MDSC immunoinhibitory function.
• Monitoring tumor growth and survival for evaluating combined DDP and CIK therapy.

Main Results:

• Cisplatin (DDP) treatment selectively decreased MDSC percentages in the B16 melanoma model.
• DDP modulated MDSC surface molecules and attenuated their immunoinhibitory functions.
• Combined DDP and CIK cell therapy demonstrated a synergistic antitumor effect against B16 melanoma.

Conclusions:

• Cisplatin (DDP) selectively downregulates the frequency and immunosuppressive function of MDSC in a murine melanoma model.
• DDP's immunomodulatory effects on MDSC contribute to its potential as an adjuvant therapy.
• The combination of DDP and CIK therapy offers a promising strategy for enhanced melanoma treatment.